Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.
From Trial to Treatment: Applying the Latest Evidence in mCSPC Management
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
4
FDA updates in urology: July 2026
5